Saltar al contenido
Merck

Type I, II, and III interferon signatures correspond to COVID-19 disease severity.

The Journal of infectious diseases (2021-05-27)
Myung-Ho Kim, Shadi Salloum, Jeffrey Y Wang, Wong Lai Ping, James Regan, Kristina Lefteri, Zachary Manickas-Hill, Ce Gao, Jonathan Z Li, Ruslan I Sadreyev, Xu G Yu, Raymond T Chung
RESUMEN

We analyzed the plasma levels of interferons and cytokines, and the expression of interferon-stimulated genes in peripheral blood mononuclear cells in COVID-19 patients with different disease severity. Mild patients exhibited transient type I interferon responses, while ICU patients had prolonged type I interferon responses with hyper-inflammation mediated by interferon regulatory factor 1. Type II interferon responses were compromised in ICU patients. Type III interferon responses were induced in the early phase of SARS-CoV-2 infection, even in convalescent patients. These results highlight the importance of type I and III interferon responses during the early phase of infection in controlling COVID-19 progression.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Millipore
MILLIPLEX® Human Cytokine/Chemokine/Growth Factor Panel A - Immunology Multiplex Assay